Cartherics is pleased to announce that Dr Vera Evtimov, Project Manager and Principal Scientist, will be presenting her work in ovarian cancer research at the European Society for Medical Oncology Targeted Anticancer Therapies Congress, ESMO TAT 2023, in Paris this March.

ESMO TAT, known as “The Home of Phase I in Oncology”, is the leading congress focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development.

This congress will be dedicated to improving the conduct of early anti-cancer clinical trials, bringing together those who are developing the most promising new cancer drugs and unveiling exciting new data.

Vera’s abstract, titled CRISPR/Cas9-induced knock-out of DGKaz in TAG-72 CAR-T cells improves function and persistence in ovarian cancer, will be presented in the poster session on Monday 6^th March, 5.15pm – 6.15pm (CET).

“This is a great conference to attend as its focus is on early phase clinical development. There are interdisciplinary attendees including academia, industry, clinicians and regulators, providing breadth of insight into the current ‘state of play’ in targeted therapies,” said Dr Evtimov.

Dr Evtimov is the recipient of a ESMO Merit Travel Grant to attend this conference.